The company was founded in 2008 and specializes in providing in vitro diagnostic reagents and supporting instrument products and integrated emergency and critical illness treatment. Currently, the company's main business has covered nearly 5,000 medical institutions in 30 provinces, municipalities directly under the Central Government and autonomous regions across the country, while also achieving a sales layout in various regions such as Asia, the European Union, and South America. In the fight against the COVID-19 epidemic, Mingde Biotech urgently developed a COVID-19 nucleic acid test kit and obtained a registration certificate, becoming a representative IVD enterprise in the affected area. At the same time, Mingde's COVID-19 nucleic acid reagents, antibody detection reagents, and blood gas analyzers have also obtained CE approval from the European Union and are eligible to be sold abroad. The company is mainly engaged in R&D, production, sales and service of in vitro diagnostic reagents and diagnostic instruments, and is committed to becoming a leading enterprise providing innovative and leading medical service products to medical institutions. The company's main products and services cover three areas: in vitro diagnostic reagents and instruments, emergency and critical illness informatization solutions, and third-party medical testing services. In addition, the company has other businesses such as selling a small number of proxy products and selling mobile square cabin PCR laboratories. Corporate honors: China's top 100 influential pharmaceutical companies, the top ten POCT brands recognized by the inspectors, etc., the outstanding enterprises in innovation and development in 2017, and the second batch of invisible champions in key industrial segments in Hubei Province.